Presentations- Advancements in Gene Therapy and AAV Vector Technology: Insights from the Penn GTP
Introduction: The Gene Therapy Program (GTP) at the Perelman School of Medicine at the University of Pennsylvania is making significant contributions to the field of gene therapy. Led by James M. Wilson, MD, PhD, the program focuses on advancing genetic medicines and exploring the potential of adeno-associated virus (AAV) vector technology. The GTP’s innovative research […]
IMPT-314: Advancing the Treatment Landscape for Aggressive B-cell Lymphoma
ImmPACT Bio USA, Inc. has achieved a major milestone in the realm of relapsed/refractory aggressive B-cell lymphoma treatment, as the FDA grants fast track designation to their groundbreaking CD19/CD20 CAR T-cell therapy, IMPT-314. In a pivotal investigator-led phase 1 study at UCLA, IMPT-314 showcased exceptional efficacy and safety outcomes, with no instances of cytokine release […]
Gilead Sciences: Upgraded Outlook and Promising Growth Path
Gilead Sciences (NASDAQ:GILD) recently received an upgrade from BMO Capital analysts, who raised their price target for the stock from $90 to $100 per share and changed their rating to Outperform from Market Perform. The analysts highlighted three key factors that contributed to this upgrade: Gilead’s outstanding cell therapy franchise, the strengthening solid tumor oncology […]
With FDA Submission For Sickle Cell Gene Therapy, Bluebird Bio Can Potentially Have 3 Approved Products By 2023
Bluebird Bio Inc, a prominent biotechnology company traded on the NASDAQ under the ticker BLUE, has recently submitted a comprehensive Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval for its groundbreaking gene therapy known as lovotibeglogene autotemcel, or lovo-cel, to be used in patients aged 12 and older who […]
Pharma.Aero adds five new associate partners
Excerpt Cross-pharmaceutical industry collaboration platform Pharma.Aero has further expanded its global network of life science and medtech stakeholders by adding HAZGO, Topa Thermal, SmartCAE, Nippon Express and Air Cargo Logistics as associate partners. Article Summary Frank Van Gelder, secretary general of Pharma.Aero, observed of the group’s partners: “All of them are concentrating on specific […]
Nippon Express Obtains GDP Certification of Compliance with WHO Standards at 2 Domestic Locations: West Japan Pharmaceutical Center and Kyushu Pharmaceutical Center
Article Nippon Express Co., Ltd. (hereinafter “Nippon Express”), a group company of NIPPON EXPRESS HOLDINGS, INC., has acquired Good Distribution Practice (GDP) certification for its West Japan Pharmaceutical Center (Neyagawa City, Osaka Prefecture) and Kyushu Pharmaceutical Center (Kitakyushu City, Fukuoka Prefecture), evidencing their compliance with WHO standards for the proper distribution of pharmaceuticals. The former […]
Eli Lilly to help fund cold chain initiative
Excerpt $1.15m funding from Eli Lilly and Company will support a new cold chain capacity initiative in low- and middle-income countries, to help improve medicine access. Article Summary To help expand access to medicines in low- and middle-income countries (LICs) Eli Lilly and Company has announced it will provide $1.15m to a new cold […]
BAS completes Bahrain airport cargo cooling units’ upgrade
Excerpt BAS had initiated the launch of a project to modernise these refrigeration units for air cargo parcels and goods located on the western side of Bahrain International Airport Article Summary Bahrain Airport Services (BAS) has completed the work related to the modernisation of cargo cooling units at the Bahrain International Airport. The move […]
BioNTech Expands German Plant as Scholz Vows to Help Pharma
Excerpt BioNTech SE has completed construction at a German facility for making a key ingredient in its messenger-RNA vaccines, the sort of investment that pharma leaders fear is becoming less attractive in Europe. Article Summary Chancellor Olaf Scholz welcomed the milestone while visiting the plant, saying Germany needs to do more to help healthcare […]
Nexcella, Inc. Entered into an Agreement with a US Cell Therapy Manufacturer
Nexcella, Inc, a biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications has announced that it has entered into a manufacturing agreement with a well-known United States Good Manufacturing Practice (GMP) cell therapy manufacturer that will supply a US Phase 1b/2 clinical trial of NXC-201 in relapsed/refractory […]
Kite and Arcellx Teams Up to Co-develop and commercialize Late-Stage Clinical Candidate- ddBCMA for the Treatment of Multiple Myeloma
Kite, the cell therapy company, has announced that it has closed global strategic collaboration to co-develop and co-commercialize Arcellx’s lead late-stage product candidate, CART-ddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma. Article Summary CART-ddBCMA is Arcellx’s T-cell therapy utilizing the company’s novel synthetic binder, the D-Domain. This candidate is currently being […]
GreenLab Unveils New Proprietary Vector Technology Platform
GreenLab, Inc. has announced the launch of its proprietary vector technology platform. GreenLab Vector Technology (GVT) greens recombinant protein manufacturing by transforming novel proteins into highly scalable corn multiplied exponentially across acres of cornfields. It offers unlimited scaling capacity for designer protein manufacturing. Article Summary With yields up to 100X greater activity than conventional methods, […]
